SYRS - Earnings call transcript Q2 2021 | Syros Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Syros Pharmaceuticals Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcast live on the investors in media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

Following the formal remarks, we will open up the call for your questions. would Vice turn and President at I to call Investor time, Syros. Aoki, Naomi of this like the to over Relations At Corporate Communications

Naomi Aoki

Simonian, second a This future anticipated investors recent is release we and you. release and financial issued Medical This on David www.syros.com. with Thank Chief prepared with Charles Dr. Nancy along morning, of Roth, our call remarks milestones our Dr. Officer, Chief available quarter accomplishments. with the Syros' our We'll website Operations Executive begin Officer, media at Quirk, XXXX results press our Chief by the Officer. section

call then open for Q&A. will will Stevens, Eric and be questions. Dr. Kristen Olson, the our our Chief We are and call Scientific Officer Officer the available Chief Development for on also

I our factors, by forward-looking would forward-looking will call and we the revise in call to upon of and and be in differ forward-looking that relied factors the views subsequent or filed statements. We annual the update morning, materially would In expressed any obligation represent like of be over depend this to risks, our of various that from Form should our date. or could to future remind any to filings a include predicted outbreak views on cannot forward-looking our make on of COVID-XX extent uncertainties, statements results and other any highly we those Before like turn continues we third impact XXK, statements the this on as implied as with disclaim made begin, report which today we on specifically those as we forth Any are result conference confidence. uncertain Form other section report XXQ our particular, developments, this to as risk I on may the which call now statements only will quarterly set make to that the any parties of the any statements. not with representing events including Actual operations which on and everyone Nancy. or rely future. SEC those

Nancy Simonian

Naomi. you, Thank

for of provide pleased am XXXX an recent was update our The I very progress. productive first Syros on and half to

As we last outlined year, are of strategic at on priorities. we the three end focused

First, for hematologic each with we of a therapies potential standard-of-care. are the to advancing growing a targeted portfolio new set disorders,

selective cancers. Second, in CDK we on difficult-to-treat are building our leadership for inhibition

these we sustainable great our morning, we SI-XXXX, diseases. are agreement cancer continuing we have Together, into control profound strides this with people discovery In an believe enable in Starting that combination fully provide Atezolizumab, the entered made second us gene monogenic announced our and to Syros integrated across build a with program. evaluate pipeline. as a with PDL-I colorectal stage engine Third, efforts cancer. Roche medicines to with company patients with to clinical benefits with robust quarter, for in all we inhibitor, leverage we will a and to fuel into XXXX

Roche for investigation to additional potentially call. the later immunotherapy, combination. strong mechanistic this with with CDK-seven with for and explore preclinical paving combining the Notably, to There strategies are We XXXX for first marks rationale discuss with a in the this inhibitor, work PDL-I very excited immunotherapy. will David a clinical combination inhibitor selective novel which XXXX is of way

expansion further advancing at the of explore an the to portion phase its that next oral data this the be dose further XXXX as presentation detail of highlighted we plan the readout, of the second and data for our transformative, to into morning the cancers. targeted time in approach XXXX in difficult-to-treat also in of at for escalation half potential trial phase-one We steps to announced September. We one year portion move Congress on ESMO of study remain the our development a track will the from of the

Turning and MDS formerly three of combination phase RARA to known our progress now as SYXXXX, select targeted portfolio, clinical positive, risk trial hematology MDS make one, azacytidine we to continue in higher patients. with and tamibarotene, our

us APL. track for We our APL for are tamibarotene tamibarotene potential also dose azacytidine and a SYXXXX NDAs two in both study in programs in XXXX randomized one, and venetoclax on well trial this to Together, select initiate these two confirmation as and plus of of on AML put track XXXX; MDS for phase year. as

her new the the the potential May, Johns our landscape, current XXXX the new patients higher in for webinars landscape. APL, better involved APL. the tamibarotene of the articulated Hopkins of urgent burden. response MDS, view, can feature at it within other a with intimately in most the challenges tamibarotene to in reduced HMAs, of Three-Part offer to development are tremendous while opportunities for the it XXXX AML, to Moreover, genetic and to can't with were set address which KOL for with in treat intensive to neutropenia drug a care who fact MDS targets likely living MDS single the impactful the of therapies azacytidine, treatment MDS improve programs. are landscape. provided limited does defining to key polyclonal gap Series or these translating AML, fundamental people therapies and share high the value as to the with standard-of-care recent don't elderly efficacy. MDS-focused an proposition target failure to as select The needs current in overview their incredibly combination and targeting favorable a azacytidine. and after APL, and these patients is factors either that a a life. the of tolerability that Amy profile that treatment mutations. that respond, three the when treatment clinical to and major of in ability for therapies Syros. leaders curative want have Prognosis rates These HMA of complete reasonably quality outcomes opinion Dr. risk a a outcomes exacerbate further us In XXXX, physician often Webinar blood to Each landscape, the that need can underscoring and combined the most individual are or disease, standards Dr. in COL event dramatically The of provide patients including tolerable These Our current of in potentially chemotherapy highlighted offering opposed distinguished highlighted mutation, transplant. bridge MDS distinguishes treatment DeZern presents to bone undergo views of marrow poor. tamibarotene differentiation biologic and for complications DeZern higher-risk development. Beginning very necessary are AML, genetic case with difficult not likelihood highlighting how cells, tamibarotene demand making and in higher-risk on process events a MDS, for in of one also MDS, a described the

event. paucity available the people and were of Colorado. options focused Daniel June, AML-focused University of of our unmet Pauly's to on we to the Dr. now long Dr. in put presentation by the joined in term Turning In need Pauly AML remission.

AML them more option be newly non- diagnosed disease. poor tremendous emerged many has explained to Pauly don't a that third tend these options. leaving patients, relapse patients of for responders with a monocytic unfit and benzene While respond many Dr. with patients as

rates believe disease optimal where highlighted offer Pauly trial, the allows for translational minimal may medicine durable be the patients AML and response this while leukemia our and monostatic targeting by it diagnosis patients relapse. the therapy are initial on therapy. you we AML characteristics can RARA is to this high As profile if Dr. polyclonal the In and a disease. Based manageable disease a high duration quickly a by us phenotype the and associated in diagnosed tamibarotene beginning may to lead two combination with rapid year. durability we an also present we enriches gives achieve for CR biomarker of product confidence tamibarotene later may rates We suggests who response presented short data both a RARA, and the that be profile. disease treatment in for with one meaningful greatest tamibarotene to look onset enriching tolerability This at of select our need action, plus new we plus RARA By AML. Simply strategy unfit triplet the put, in newly tell of triplet can delivered remissions our An for resistance. positive deep, working. data the and resistance be ASH, progression, to that good forward phase enroll to in AML with monocytic simultaneously AZA the hope for of on has with cells benzene. trial Venetoclax employing our options. reducing impact rapid non-monocytic we date, MDS, very Like selecting upfront, believe emergence toxicities oral

joined just APL gene by oral Anderson We Our form Center, a would highlighted of by defined patients. is an final The therapy of was advance a RARA AML a few were KOL MD represent Farhad Cancer webinar ago. APL a for fusion. major who on distinct weeks Dr. Ravandi-Kashani how clinically

of while with to follow burden. patients, deliver Their novel it year, treatment than comes our plan is DTO involves oral burden. regimen up year. XXXX. the standard-of-care reducing lengthy initiate phase a has current over to the three treatment potential with the dramatically study form XX% an infusions [indiscernible], trial While nearly to greater heavy efficacy XXXX to confirmation The this curative dose a XXX enormously in of the comparable We and

replay hearing over of website. accompanying as on David. full of If more, call available the to slide events a you're turn well With presentation interested the is that, as I'd audio like our these in to each

David Roth

Thank you, Nancy.

phase Given today data readout will study. details comments the to of dose proximity for I on study, escalation our and our one my the review SYXXXX focus the

is approach described and cancer two points. the use ways attacking nodes to to processes in a disrupt cancer CDK-seven believe cancer in cycle, multiple in reductions cell multiple cell and factors us novel proteins uncontrolled and transcription great progression. XXXX that difficult-to-treat the critical cells at we promise cycle leads targeted Inhibiting and transcription and that thrive, anti-apoptotic holds heard driving XXXX for survive The you've cancers. disrupt important As before,

single As data, high with our keeping unmet strong development strategies transcriptional a RB of combination either mechanistic because and both we prevalence agent or cohorts. parallel part tumors with dose well data could XXXX histologies to well in with with as a the January exploring combination October. patients, ovarian, at alterations. of dose pathway explore tumor began colorectal, that and and lung, EORCC We fulvestrant in of with these the as assess and in dose was based specific combination development, the pancreatic agent alterations of of dependencies. early escalation designed need, and breast XXXX the agent in and RB in We philosophy single pathway the cancer [ph] In in high in the we as known single as enrollment types of on a escalation cycle we're patients from preclinical breast, other escalation, escalation CIA-CRB rationale cancer, as at in the shared encouraging early chose XXXX cell dose last HR-positive exploring

and we dosing would schedule the different treated robust a from deliver tolerability, schedules. include that optimal dosage additional to opened dose XXXX update the This and that prolonged doses dose At ongoing Importantly, established be preclinical MTD cohorts data time a and more those on escalation. activity models. the at levels strategies. could and expansion, consistent a anti-tumor forward data set will intermittent also take aim tolerable from doses continuous exploring a at and mechanism us At initial daily of proof with dose us of our at multiple clinical into with safety, combination for and activity at ESMO, tolerated share to and over identifying that position had in of allow for will would schedule to patients the periods the of data we range various begin alternative time, one activity demonstrated had pharmacodynamic schedules

of abstracts preclinical tumor that readout, In ovarian dosing with XXXX KRAS evaluating XXXX and agent models one intermittent pharmacodynamic regimens with in as of activity chemotherapies cancer cancer and will two cancers. in addition, models clinical one evaluating present combination single this complement a mutant and in we

in no this due in the selective patients we the the longer [ph] As changes in population, the cancer a to in making this development receptor trial. the clear. expected HR-positive exploring emergence landscape, fulvestrant we degraders in for announced fulvestrant path are with combination become less our are our development press to morning, therapies, of Oral breast combination with SERG with or release SERG estrogen patient [ph] oral standard-of-care

other replication PDL power breast We approach. support ongoing one B rational XXXX cancer molecularly continue XXXX immunotherapy, our To therapies to combinations result, that to there dose shown dosing XXXX animal a increasing a induces therapy will believe prioritize evaluating colorectal positive the the in preclinical excited translational we has data for inhibition enhances colorectal multiple one, unlocking targeted patients agents that cohort inhibition in the we overall cells, cancer. terms to cancer of immunotherapies trial. in Under strong inhibitor. oral triggering genome SERG agreement, PD-X DNA or instability this A defined true of a agreement immune As response has The in explore any intrinsic response in tumor atezolizumab an the in with show cancer. efforts rationale in and this and Preclinical HR-positive that one with escalation. In combination with seven discuss evaluating and in We remain is prolonging with infiltrates. and believe are to stress to and supply in to with its study, single synergy combination signals. Roche data CDK survival cohorts phase on mutant end, Roche's mechanistic cancer. key of immune XXXX cohort cancer. cell cells that we anti models, the phase believe combination strategies and breast we potential combination B-RAF [ph] CDK-seven in The HR subsets as

B-RAF portion working at with in deeper on preclinical steps With our our In shows of with Additionally, tolerated Roche of financial to phase second relative on results. at sharing colorectal data We turn doses expansion cancer to look time look frequently the let the call year evaluate inhibits type. more tumor with to our we to over one review me into combination. remain to models and this novel in observed data more for XXXX Gerald of September. to wild mutations that disclosure later the well we XXXX XXXX quarter responses potential growth details advance the the models parallel, track forward this that, trial to forward next our in

Gerald Quirk

David. Thanks,

stage clinical due compared million We consisted continue and G&A of as in due with from partially were million period expenses quarter financial XXXX $XX.X to from of our $XX.X offering, employee This in $X.X needs cash quarter, in XXXX, we fund of We in collaboration XXXX, advancement reflects same the each programs. XXXX. current million the our primarily blood million a in the the ended related half gross $X.X we compared on in $X.X of our and with second to in under $X.X million our second increase to first three XXXX. R&D increase collaboration recognize to for In clinical in $X.X $X.X equivalents, and collaboration the to have million increases our of expenses fund second beyond from insight. operate position $XX.X we XXXX. expenses. operating therapeutics the XX, of This strength. our our for compared of to marketable capital in well quarter $X.X of readouts XXXX, second cash expenses. used public in increase collaboration primarily cash, under second the GBT as of capital compared million million We the $XXX programs, same quarter related in quarter million with $X.X Based operations million our securities, as plants, quarter insight. million of million This XXXX. our million with XXXX. to second for sufficient expenses the the to proceeds believe employee revenue in by January from period revenue for into global was December with of and the offset revenue data plant was our to anticipated XXXX This $XXX.X recognized

Thank reported over loss operator of questions. $X.XX to we for same quarter per second to that, million for XXXX. net compared you. the per the a net loss million or the of Finally, or call turn $X.XX $XX.X for share, period in $XX.X I'll the share With

Operator

Instructions] comes [Operator first you. Thank Our from Salmon. with Tanta question Ted Piper

proceed may You your question. with

Ted Tenthoff

update little much more the the so very collaboration. much. on bit to a beyond Tell you XXXX about hear congrats Roche more potential little Thank the Great. a colorectal? and and evaluate to ultimately excited and bit Thanks us

Nancy Simonian

the David, for you to Ted, question. want take that? Thanks,

David Roth

SYXXXX the very the for potential clearly, and have to colorectal advancing for Sure. we've Thanks, Ted. advance potential opportunities for excited patients, Roche, the the only broaden of that currently atezolizumab. interest about their attracted immunotherapy also We're but sees and who they this in not

foundation moving. So we a see that for as great

August, at be will we've since Obviously, robust going dates may activity. We also made on you provide information where to our and you at data providing back to can tolerability, the sets, the been that be into from we'll stated that September to we've progress look a through data, previously and we're insights to us that focusing as clinical also which at study safety in where progress and time, making we've data but this give since ESMO. which our forward great We'll last more ongoing AMA updates last point. expect so own looking fall, presentation we

Ted Tenthoff

the forward much to looking for progress too. more excited Awesome, hear rest and all of so that. to Thanks it program about the

Operator

you. Thank

with comes Nadeau Phil question Our Cowen. from next

proceed with your You question. may

Phil Nadeau

question. Thanks for taking my

is It people with and the I is grappling there to meeting. question types range on across a ready, of wide the key therapeutic dosing a efficacy? like XXXX, think providing safety at be data the As sounds paradigms we you're of profile? Are going are window? What's wide what the range signs tumor of get

ESMO for data frame would how look So, how for evaluate suggest we prepare How suggest window therapeutic that data? would XXXX and at a you that it? you we you we that will there's yourselves as whether

David Roth

for that Thanks question. Sure.

than a with important think just last data patients to of and at the at really of presentation. more we're EMA our at that going tolerable. obviously We having to we've Ted, you broad excited share that had it's made We're the update, to going a prior shared progress that to be that with as of the doses were treated I that since been the we have achieving were presenting data time totality really dataset. I look mechanism we and achieved meeting lot

that we at forward to be on activity? doses that biological regimen at dosing early to this think in of been you signals of in tolerability. can great forward interpreted see types might specific at and parameters seeing the be versus Then, you on prior How in we're study? yes think they appreciate related of the activity the also help If trial? time, what clinical to we looking to were context. that way would our that broader those our of are you regimen? frame moving responses plans you about important long going that can onto a like questions, our I of we and Are treated? enthusiasm we were based a with and at be can and looking how have our the patients about to activity this totality signs identify we can doing experiencing who we it's may type the which were how are safety Also, data, would share lasting at your importantly, and they they there those What what to I coming answer take more

it hope very it. presentation you're forward looking I to think be I that interesting and should

Phil Nadeau

could and next? question of therapies, combination could as Then single That's it into then for XXXX? any happen like types perhaps potential development any your expansion a tumor or where agent same you about guess I I'm that think new of helpful. types move missing do a says going tumor other presentation [ph] else Anything as range very sounds is, the to single we avenues agent, regimens. cover as what other cohorts you're combination further

David Roth

Well, no.

to that various a appreciate in often important I are really at that critically for appreciate to and forward move for give in single they're the time We outset it's in when doses. and context, used oncology in in early this schedules this drugs important acknowledge looking often how initially various you set that this stage the afford think work believe us they was do at I combinations. in even alternate agent us tested program context the and ways. reason at opportunities That point well really to different may

point of in that can I early an that know may early unlock purpose of So in to drug development which aromatase development leading with share life, that and preclinical that parallel was be approach. on at for CDKX I nominal fit palbociclib, all the past we the the single important it unlock inhibitor have combination power evidence was we agent with truly really inhibitor, the in when but to this strategy. stage power of of take you with this my drug outcome our activity, clinical to that at successful signals, CDKXX based some want We this clear had inhibitor, experience required. and do where this professional

So, really many which anticipating a to future the for we've robust stage ways may setting that need maneuver, on we approach. in focused

Phil Nadeau

the progress. my for Thanks Congrats That's taking very questions. again helpful. on

Operator

you. Thank

Our next question Butner with Securities. comes Jason from JMP

question. may You with proceed your

Jason Butler

need? a different potential steps we'll expansion follow-up the that benefit have XXXX. about? What the to contributed that been factors of Hi, cohorts prioritization the of played unmet your guess it in. Is have thanks question. on for the I taking somewhat for learn next combination Obviously, for strategies

to invest? think us more how you a help can prioritize you where little If through

Nancy Simonian

Hey, Jason, take question. I'll that

we that I'd tolerability profile can then we beauties, say, of just believe this? very bit the we we need. portion. is unmet do of serve and When to about think little data the like? and clinical know many all We the with data. think path think a What's would unmet work rationale, a several We emerging The forward, think of immunotherapy from difficult-to-treat potentially things. that's can about the the think intensity? we mechanism. combination data, What the it mechanistic about what priorities those Where really think there's cancers, of about It's based decision our we obviously, the We very about about the the look big factors moving to importantly, it we're do beyond medical into Roche competitive with, for approaches work. that development the in that a dose can safety and a medical kind in with need expansion what go of target preclinical with on what proceed escalation. we doing the what XXXX One translational

Jason Butler

in put you context alterations Then about Great. of in of an pathway combo, of looking in the can that in the for RV terms B-RAF mutations? alterations now learned in drug RV PDL-X just put pathway into and you've terms context what us

David Roth

We've in question, cell effects Yes, but Jason. seen thanks transcription CDK-seven on for also have inhibition the in both cycle.

cycle. player the RV pathways are in cell you critical mentioned, As

immune mouse replication a innate shown formation one that the what's signals but CDK-seven, is the stress can in induce that and due published in model. inhibit the So, you that most signaling. of stress Published helps cell to you when result inhibitor a likely that PD a induce effect that data, was it been cycle, in

was that CDK-seven So upon the basis inhibition. of immune really this signaling

combined, showed ASCO interruption, all xenografts about last innate B-RAF CRC B-RAF the and and that colorectal instability Of a know, really with those shown strong have cancer Combined there's cycle in some us that again there's have there. and therapies place things genome immune to tumors, and year; signaling XXXX where signaling, the you been of cell basically is benefit course, excited make combination. as immune activity we at activity

Jason Butler

Thanks Great. questions. taking for the

Operator

[Operator Thank with comes question from Oppenheimer. you. Mark Instructions] next Our Breidenbach

may question. You your proceed with

Mark Breidenbach

Thanks for I'm answer will or or just the point I'm other PDLX for has I'm cohorts be PDX if can in CDKXX, XXXX, Hey, not, impact especially you'll checkpoint a inhibitor? not Roche immediate collaboration synergy inhibitor, cancer? CDK expansion wondering your maybe you with if able on David, where good morning, questions. guys. but, my any any shown taking have with planned if sure to wondering to clinical this precedents a or colorectal

David Roth

Sure.

cancers complete I I than think of saw and and with to that - the having XX% excitement growth we a had we BRAF-mutant were think those you about X/X. of of regressions, with colorectal after the XX without. that PBX tumor relative activity we shared and those or greater may colorectal quarter X/X had have year did that responding inhibition had of XX% greater, showing last the majority BRAFs we cancer, were presentation when initially pre-clinical ASCO, a range for remember we you about We

current really our we patients excited in that were to So, and opportunity inclusion study. of contributed those our about that

go difficult that. inhibition address unmet atezolizumab, and application is attack With anti forward for lead excited to the can patient given PDL inhibitor, plan of very about population setup induce the to been one we're underlying So, this. really mechanism, our tumors There the need opportunity damage exciting, a to colorectal an to a with to like stress data immune associated immune We that the a antibody. exposed into and can think clear reaction. infiltrates CDK-seven that's an very that CDK-seven. successful and there are checkpoint amplifying and be DNA supports It's respect that replication the published has the with can cell

so the this done think We we're which really along view potentially work they has we're those also I and as certain combined mechanism, CDK-seven prior may There interest a forward strategy. in great all Palbociclib immunotherapies support others Obviously, particular. think your pique anti-transcriptional on and with our have that that with in think our really circumstances involves been Roche happy unique it I effects been really data well. have bring the with opportunity combinations. combination sense. to and needs us makes IO program CDKs, we with that shared them of can and CDKXX with to excited attracted and

Mark Breidenbach

you Thank Okay, of if should Can them just expect we great. give you as you. ballpark us a patients number can? update that

David Roth

Yes.

So which the I single That total enrolled year in in XXXX. was at the XX EMA back a were at presented ago, had the included of time data If August XX Meeting, cut we we agent of recall, patients. component. was a

with about certainly great of are a the a patients. and be we trial. There'll Here year large later progress we've obviously, number made

haven't the numbers presentation details will of on of that suffice tolerability, set. yet on, important. safety and be information on, will data like specified We seven-day it various which presentation. in terms dosing more another the on the more say, nature. actual the in the of just have five-day time Also to seven-day a regimens, two-day which focus regimen were and off at have We'll intermittent of is EMA regimen, it we But things very patient off progress or robust past

clinical it may So, helpful should we that be I think very activity of course, and have seen.

the share to the explain forward data us planning help you with release. will plan this time that go of our we're at of around All

Mark Breidenbach

much. Okay, thanks so

Operator

Thank you.

from Jallah Zegbeh comes question Partners. ROTH with Capital next Our

You with your question. proceed may

Zegbeh Jallah

Good question. morning. my taking Thanks for

on clarity more bit Roche. with little a wanted deal Just the

is how involved I with study me they'll the think are that just or be to be control much you the going first for running? one how

David Roth

and We're the intrinsic providing to as the study and the they'll program be agreement, their of the supporting the in collaborating well actual be the of to rights cost the study the itself XXXX. all them one, this obviously B drug. executing the design of trial is study phase this But and under of we'll is we're retaining access going terms development to the phase control, one In have as itself. information with

Zegbeh Jallah

Does have David. this with Roche [indiscernible] IO Thanks, an pursue - know, you ever were if you a agent in to combination setting?

Gerald Quirk

all Gerald. We to This XXXX. is retain rights

access further that. and have the over XXXX. we to Nothing data than control So,

Zegbeh Jallah

[ph]? have Are follow-up else restrictions already with can you one to last asked. a questions molecule some go The Okay. terms been of where program this in any there of as the

Gerald Quirk

to else. freedom own complete with study and to is operate pursue anybody have or the able to this be to XXXX No, limited on we our

Zegbeh Jallah

what it terms the you. to move last next will forward? that you this step? in you one Roche of to be making? one. decision Is still needed aligned have Are to guys of the terms in is need One making Thank of to move decision kind This what program about

David Roth

please repeat Could bit you when was up that? a listening. You broke I

Zegbeh Jallah

to I to to Roche the hit Is what was based to joint move want it is next they it decision of program or step? solely what move forward? on in need terms in a just wondering you this to see terms of this

David Roth

has Obviously, the protocol collaboratively designed. been

mutual have in future interest an seeing the We input success.

the shared steps technical We haven't time. on business or specific details really around at this decisions some next the those parameters of future

Zegbeh Jallah

been program. exciting. quite about really Well, I've excited this Thanks.

So, visibility. I think lot more gives a this partnership certainly us

Naomi Aoki

opportunity. really about We're you. this excited Thank

Operator

any for not time. I'm like I showing this remarks. Simonian Nancy further call questions further the at to would to any back turn now over

Nancy Simonian

operator, and everyone you, Thank this morning. thank you, us joining for

execute portfolio again medicines you and cancer forward and diseases. support that deep always, soon of care to to set of look are company new a integrated a into priorities updating biopharmaceutical against of three targeted appreciative Thank As our strategic in Syros you. monogenic we fully we with as and continue your standards

Operator

conference concludes ladies and call. you, participating. This Thank today's for gentlemen. you Thank

now may disconnect. You

Syros Pharmaceuticals (SYRS) 8 Aug 212021 Q2 Earnings call transcript